Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study
Kristina M. Brooks(National Institutes of Health Clinical Center), Patricia M. Flynn(St. Jude Children's Research Hospital), Ann M. Buchanan, Jaime G. Deville(University of California, Los Angeles), Yasha Rani(Frontier Science & Technology Research Foundation, Inc.), Lauren Ziemba(Boston University), Haseena Cassim(University of the Witwatersrand), Kevin J. Ryan(University of Alabama at Birmingham), Faeezah Patel(University of the Witwatersrand), Shaun Barnabas(University of Cape Town), Hardik Chandasana(Simulation Technologies (United States)), S. M. Ward(Frontier Science & Technology Research Foundation, Inc.), Anne Coletti(Family Health International 360), Iris Mustich(Family Health International 360), Chelsea Krotje(Frontier Science & Technology Research Foundation, Inc.), Ponego Ponatshego(Gaborone University College Of Law and Professional Studies), Helena Rabie(Stellenbosch University), Dwight E. Yin(National Institutes of Health), Sai Majji(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Jack Moye(National Institutes of Health), Linda Aurpibul(Chiang Mai University), Gaerolwe Masheto(Botswana Harvard AIDS Institute Partnership), Jennifer J. Kiser, Barbara Heckman(Frontier Science & Technology Research Foundation, Inc.), Mark Lojacono(Frontier Science & Technology Research Foundation, Inc.), Edward P. Acosta(University of Alabama at Birmingham), Cynthia H. Brothers, Ellen Townley(National Institutes of Health), Tim R. Cressey
Cited by 13
Related Papers
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
|The Lancet|2022|16k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k